CHANTILLY BIOPHARMA
DEAD

Serial Number

85390392

Owner

Chantilly bioPharma LLC

Attorney

CRAIG M. BELL

First Use Date

Mar 20, 2011

Filing Date

Aug 5, 2011

Add to watchlist:

No watchlists yet
View on USPTO

CHANTILLY BIOPHARMA Trademark

Serial Number: 85390392

CHANTILLY BIOPHARMA is a trademark filed by Chantilly bioPharma LLC on August 5, 2011. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Chantilly bioPharma LLC

3701 Concorde Parkway
Chantilly, VA 20151

Entity Type: 16

Trademark Details

Filing Date

August 5, 2011

Registration Date

Not Registered

First Use Anywhere

March 20, 2011

First Use in Commerce

March 20, 2011

Goods & Services

Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Antimicrobial preservatives for cosmetics and pharmaceuticals; Astringents; Balms for pharmaceutical purposes; Cardiovascular pharmaceuticals; Cellulose esters for pharmaceutical purposes; Cellulose ethers for pharmaceutical purposes; Charcoal for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for active pharmaceuticals; Dermatological pharmaceutical products; Digestives for pharmaceutical purposes; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for pharmaceutical actives that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Ferments for pharmaceutical purposes; Gelatin capsules sold empty for pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of colds and the flu; Hyaluronic acid for pharmaceutical purposes; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Inhalers filled with pharmaceutical actives; Injectable pharmaceuticals for treatment of anaphylactic reactions; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension

Filing History

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jul 5, 2012 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jul 5, 2012 ABN2
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
Dec 8, 2011 CEPE
ASSIGNED TO LIE
Dec 8, 2011 ALIE
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Dec 8, 2011 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Dec 8, 2011 GEAP
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Dec 8, 2011 CPEA
ASSIGNED TO EXAMINER
Nov 30, 2011 DOCK
NOTICE OF PSEUDO MARK MAILED
Aug 10, 2011 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 9, 2011 NWOS
NEW APPLICATION ENTERED
Aug 9, 2011 NWAP